Irinotecan News and Research

RSS
Irinotecan hydrochloride is approved by the Food and Drug Administration (FDA) to be used with other drugs to treat colorectal cancer that has metastasized (spread to other parts of the body). It is also approved to treat metastatic colorectal cancer that has recurred (come back) or gotten worse after earlier chemotherapy. In addition to the uses that have been approved by the FDA, irinotecan hydrochloride is sometimes used to treat other types of cancer. Irinotecan hydrochloride is also being studied in the treatment of other types of cancer.
Triplet therapy could benefit patients with BRAF-mutant metastatic colorectal cancer

Triplet therapy could benefit patients with BRAF-mutant metastatic colorectal cancer

New trial shows improved survival for patients with advanced colorectal BRAF-mutant cancer

New trial shows improved survival for patients with advanced colorectal BRAF-mutant cancer

Study: Three-drug combination improves overall survival in patients with mCRC

Study: Three-drug combination improves overall survival in patients with mCRC

New drug combinations and dosing schedules improve outlook in advanced colon cancer

New drug combinations and dosing schedules improve outlook in advanced colon cancer

UA scientists aim to identify drug targets for rare pediatric cancer

UA scientists aim to identify drug targets for rare pediatric cancer

Toxic effects of drugs in the lungs 'more widespread than thought'

Toxic effects of drugs in the lungs 'more widespread than thought'

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Phase III LONSURF study shows progression-free survival in patients with refractory metastatic gastric cancer

Phase III LONSURF study shows progression-free survival in patients with refractory metastatic gastric cancer

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Multi-strain probiotic helps reduce chemotherapy-induced diarrhea in cancer patients

Multi-strain probiotic helps reduce chemotherapy-induced diarrhea in cancer patients

Comprehensive analysis reveals weaknesses to target in common pediatric solid tumor

Comprehensive analysis reveals weaknesses to target in common pediatric solid tumor

CNDA approves KEYTRUDA for treatment of advanced melanoma

CNDA approves KEYTRUDA for treatment of advanced melanoma

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Researchers explore targeted second-line treatment for colorectal cancer

Researchers explore targeted second-line treatment for colorectal cancer

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

Study confirms safety and efficacy of new second line treatment for metastatic colorectal cancer

Study confirms safety and efficacy of new second line treatment for metastatic colorectal cancer

Gut bacteria composition could predict toxicity of chemotherapy drugs in cancer patients

Gut bacteria composition could predict toxicity of chemotherapy drugs in cancer patients

FDA grants approval for new biosimilar to treat multiple types of cancer

FDA grants approval for new biosimilar to treat multiple types of cancer